PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
11.35%
Net income growth 1.25-1.5x CRVO's 9.19%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
1.31%
Less D&A growth vs. CRVO's 88.21%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
-12.55%
Negative yoy SBC while CRVO is 63.46%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-199.74%
Both reduce yoy usage, with CRVO at -244.25%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
A yoy AP increase while CRVO is negative at -180.74%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-382.74%
Negative yoy usage while CRVO is 111.08%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-25.35%
Negative yoy while CRVO is 0.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
2.31%
Operating cash flow growth 1.25-1.5x CRVO's 1.78%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
83.69%
CapEx growth of 83.69% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.69%
We expand invests by 83.69% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
3875.79%
Issuance growth of 3875.79% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.